DDInter1268 DDInter350
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Melphalan
Melphalan {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Chlorambucil
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Chlorambucil
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Melphalan
Melphalan {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Chlorambucil
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Efalizumab
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Ustekinumab
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Melphalan
Melphalan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Chlorambucil
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Natalizumab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Chlorambucil (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Chlorambucil (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Chlorambucil (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Chlorambucil (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)